Acrivon Q2 FY26 net loss narrows 14.48% to $18 million
ACRV•Cash position and program updates
Cash, cash equivalents and marketable securities totaled $90 million at June 30, expected to fund operations into Q4 2027.
- ACR-368 Phase 2b interim analysis remains on track for H2 2026.
- ACR-2316 moved into randomized dose expansion with 120 mg and 160 mg.
Q2 loss narrows as expenses decline
Acrivon Therapeutics posted a Q2 net loss of $18 million, narrowing from $21 million a year earlier.
- R&D expense fell to $13.8 million from $16.2 million, on non-recurring ACR-368 milestone costs booked in 2025.
- G&A expense declined to $4.8 million from $6.5 million, driven by lower employee-related costs including stock-based compensation.
